Welcome to our dedicated page for Nucana SEC filings (Ticker: NCNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NuCana plc files as a foreign private issuer, and its SEC materials document Form 6-K current reports, UK annual report materials, annual general meeting notices, and voting procedures for holders of American Depositary Shares. The filings connect the company’s ordinary-share governance with its ADS program and describe how depositary voting instructions are handled for shareholder meetings.
Recent filings also furnish financial results, unaudited condensed consolidated financial statements, management discussion and analysis, and clinical-program updates for NUC-7738 and NUC-3373. Other disclosures cover patent announcements, board and executive-role changes, Nasdaq continued-listing compliance for the ADSs, and incorporation of selected 6-K information into registration statements on Form F-3 and Form S-8.
NuCana plc reported that it held its Annual General Meeting on June 8, 2026 at Lochside House, 3 Lochside Way, Edinburgh, United Kingdom. All resolutions contained in the company’s AGM notice dated May 6, 2026, which had been furnished on Form 6-K, were duly proposed and passed.
NuCana plc, a clinical-stage biopharmaceutical company focused on improving cancer treatments, has appointed Ian Webster as Chief Financial Officer, effective June 1, 2026. He has been Interim CFO since June 2025 and previously served as Director of Finance after joining in 2019, and will continue as Principal Financial and Accounting Officer.
The company highlights its oncology pipeline, including NUC-7738 and NUC-3373. It plans to generate data in 2026 from the Phase 2 NuTide:701 study of NUC-7738 in combination with Keytruda in PD-1 inhibitor-resistant metastatic melanoma and to refine a potential registrational strategy in melanoma. NuCana also notes multiple anticipated data readouts and a cash runway anticipated to extend into 2029, supporting its clinical and strategic plans.
NuCana plc reported first quarter 2026 results showing a net loss of £3.9 million, wider than £2.5 million a year earlier, driven mainly by higher research and development spending. Cash and cash equivalents were £21.5 million as of March 31, 2026, and the company anticipates this will fund planned operations into 2029.
The pipeline is led by cancer drug candidate NUC-7738, now in the Phase 2 part of a Phase 1/2 study, including a Phase 2 NuTide:701 expansion in PD-1 inhibitor‑resistant metastatic melanoma. The FDA cleared an Investigational New Drug application for NUC-7738 in April 2026, enabling U.S. clinical studies initially focused on melanoma.
NuCana also continues to develop NUC-3373, a thymidylate synthase inhibitor evaluated in a Phase 1b/2 study in combination with pembrolizumab and with docetaxel. The company remains pre‑revenue and expects to continue incurring losses as it advances clinical programs and explores additional indications and combination strategies.
NuCana plc has published its 2025 UK Annual Report and called a 2026 annual general meeting on 8 June 2026, asking shareholders to approve key financing and governance resolutions.
The board stresses that passing all AGM resolutions is essential to avoid severely compromising the company’s ability to finance its plans. Proposals include a 1:100 sub-division of existing ordinary shares, creating new ordinary shares with a much lower nominal value and a large class of non-voting deferred shares, so the company can issue new ADSs despite a low market price.
Shareholders are also asked to authorise the board to allot or grant rights over shares up to a nominal £5,000,000 and to disapply pre-emption rights on the same amount, giving flexibility to raise equity quickly and to maintain option and incentive plans. The report highlights NuCana’s lead oncology programs NUC-7738 and NUC-3373, ongoing Phase 1/2 development, and data suggesting combination potential with PD-1 inhibitors.
For 2025, NuCana recorded a loss of £29.4 million on research and development expenses of £12.7 million and administrative expenses of £8.1 million. Cash and cash equivalents were £24.3 million at 31 December 2025, and the company believes existing resources will fund anticipated operations into 2029, while acknowledging that further equity funding may still be needed if it expands development.
NuCana plc granted Chief Operating Officer Theresa Margaret Bruce options over 132,600,130 Ordinary Shares. The options carry an exercise price of 0.0004 Pounds Sterling per share, aligning with the nominal value of the Ordinary Shares.
According to the award terms, 50% of the underlying shares vested on April 15, 2026, with the remaining half scheduled to vest in four equal annual installments, contingent on continued service. Following this grant, Bruce holds options over 132,600,130 Ordinary Shares that expire on April 15, 2036.
NuCana plc director Levy Elliott M. filed an initial statement of beneficial ownership. The filing shows direct holdings of 13 Ordinary Shares and American Depositary Shares (ADSs), where each ADS represents 5,000 Ordinary Shares.
He also reports multiple option awards over 23,811,896 and 28,631,517 Ordinary Shares at exercise prices between 0.0004 and 0.004 Pounds Sterling. Some options are already fully vested and expire between June 20, 2035 and January 14, 2036, while others are scheduled to vest in full on June 20, 2026 and January 14, 2027 subject to continued service. The filing records existing holdings rather than new market purchases or sales.
NuCana plc executive David James Harrison, Head of Translational Medicine, filed an initial Form 3 reporting holdings of options over the company’s Ordinary Shares. The filing lists several option grants, including options over 62,499,995 Ordinary Shares with a 0.004 Pounds Sterling exercise price that fully vested on June 20, 2025 and expire on June 20, 2035.
Other grants referenced include options over 1,971,417, 77,520,679 and 64,471,412 Ordinary Shares at a 0.0004 Pounds Sterling exercise price, with vesting completed on June 20, 2025 or January 14, 2026, and new awards vesting 25% on June 20, 2026 and January 14, 2027 with the remainder in three equal annual installments, subject to continued service.
NuCana plc director Mellish Martin C.B. filed an initial Form 3 disclosing his equity interests in the company. He directly holds 7 American Depositary Shares, and each ADS represents 5,000 ordinary shares of NuCana plc. He also directly holds 28 ordinary shares.
The filing lists several option awards over ordinary shares with very low exercise prices in Pounds Sterling. Some of these options have already fully vested and expire between June 20, 2035 and January 14, 2036, while others are scheduled to vest in full on June 20, 2026 and January 14, 2027, conditional on his continued service with the company.
NuCana plc Chief Medical Officer Jeffrey D. Bloss filed a Form 3 reporting his existing ownership in the company. The filing lists multiple option awards over Ordinary Shares with exercise prices between 0.0004 and 0.004 Pounds Sterling, including grants that are fully vested and others that vest between June 2026 and January 2027, subject to continued service. Bloss also reports direct ownership of 47,136 Ordinary Shares.
NuCana plc reports its 2025 annual results and outlines key risks around its oncology pipeline and funding. The company recorded net losses of £19.0 million in 2024 and £29.4 million in 2025, bringing its accumulated deficit to £252.3 million as of December 31, 2025.
Cash and cash equivalents were £24.3 million at year-end, which management believes will fund operations for at least twelve months, though substantial additional financing will be needed longer term and going-concern risk is highlighted. NuCana’s lead candidates are NUC‑7738, in a Phase 1/2 trial for advanced solid tumors and PD‑1 inhibitor‑resistant melanoma, and NUC‑3373, recently evaluated in a Phase 1b/2 trial in combination regimens. The report emphasizes extensive development, regulatory, funding, market, operational and macroeconomic risks, and notes 20,809,854,947 ordinary shares outstanding as of December 31, 2025.